115 related articles for article (PubMed ID: 35248497)
1. Adverse effect investigation using application software after vaccination against SARS-CoV-2 for healthcare workers.
Yamazaki S; Watanabe K; Okuda Y; Urushihara M; Koshikawa H; Chiba H; Yahaba M; Taniguchi T; Nakada TA; Nakajima H; Ishii I; Igari H
J Infect Chemother; 2022 Jun; 28(6):791-796. PubMed ID: 35248497
[TBL] [Abstract][Full Text] [Related]
2. Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.
Cheng Y; Li T; Zheng Y; Xu B; Bi Y; Hu Y; Zhou YH
Hum Vaccin Immunother; 2022 Nov; 18(5):2064134. PubMed ID: 35452357
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
Maruyama A; Sawa T; Teramukai S; Katoh N
J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
[TBL] [Abstract][Full Text] [Related]
5. Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study).
Risco-Risco C; Martínez-Urbistondo D; Suárez Del Villar R; Ayerbe García-Monzón L; Pérez-Rubio A; Barberán-López J; Andaluz-Ojeda D; Villares Fernández P
Rev Esp Quimioter; 2023 Aug; 36(4):400-407. PubMed ID: 37119130
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
Takuva S; Takalani A; Seocharan I; Yende-Zuma N; Reddy T; Engelbrecht I; Faesen M; Khuto K; Whyte C; Bailey V; Trivella V; Peter J; Opie J; Louw V; Rowji P; Jacobson B; Groenewald P; Dorrington RE; Laubscher R; Bradshaw D; Moultrie H; Fairall L; Sanne I; Gail-Bekker L; Gray G; Goga A; Garrett N;
PLoS Med; 2022 Jun; 19(6):e1004024. PubMed ID: 35727802
[TBL] [Abstract][Full Text] [Related]
7. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
[TBL] [Abstract][Full Text] [Related]
8. Exploring the reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: a multi-national survey study.
Amer SA; Al-Zahrani A; Imam EA; Ishteiwy EM; Djelleb IF; Abdullh LR; Ballaj D; Amer YA; El-Sokkary RH; Elshabrawy AM; Eskander G; Shah J; Raza ML; ALsafa AMAA; Ali HT; Fawzy HM
Sci Rep; 2024 Feb; 14(1):4785. PubMed ID: 38413637
[TBL] [Abstract][Full Text] [Related]
9. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
Lee YW; Lim SY; Lee JH; Lim JS; Kim M; Kwon S; Joo J; Kwak SH; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH; Bae S
J Korean Med Sci; 2021 May; 36(21):e153. PubMed ID: 34060261
[TBL] [Abstract][Full Text] [Related]
10. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
[TBL] [Abstract][Full Text] [Related]
11. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
Jeon M; Kim J; Oh CE; Lee JY
J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta's state hospital.
Cuschieri S; Borg M; Agius S; Souness J; Brincat A; Grech V
Int J Clin Pract; 2021 Oct; 75(10):e14605. PubMed ID: 34228863
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
14. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
15. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine.
Lombardi A; Renisi G; Consonni D; Oggioni M; Bono P; Uceda Renteria S; Piatti A; Pesatori AC; Castaldi S; Muscatello A; Riboldi L; Ceriotti F; Gori A; Bandera A
BMC Infect Dis; 2022 Jan; 22(1):97. PubMed ID: 35090388
[TBL] [Abstract][Full Text] [Related]
17. Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naïve and previously infected by SARS-CoV-2.
Chong-Valbuena A; De-Jesús-María I; Agurto-Ramírez A; Puchades-Gimeno F; Melero-García M
Vaccine; 2022 Jun; 40(28):3818-3820. PubMed ID: 35643563
[TBL] [Abstract][Full Text] [Related]
18. Questionnaire-based study of COVID-19 vaccination induced headache: evidence of clusters of adverse events.
Zhou Q; Eggert T; Zhelyazkova A; Choukér A; Adorjan K; Straube A
BMC Neurol; 2024 Mar; 24(1):84. PubMed ID: 38431578
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 Vaccine Hesitancy and Early Adverse Events Reported in a Cohort of 7,881 Italian Physicians.
Monami M; Gori D; Guaraldi F; Montalti M; Nreu B; Burioni R; Mannucci E
Ann Ig; 2022; 34(4):344-357. PubMed ID: 34821928
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
